Leslie Smith, MD
Psychiatry · Little Rock, ARNPI 1881803203
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $628,479 of the $766,475 with a category attached, or 82.0%. It is spread thinly across 30 manufacturers, the largest accounting for just 23.7%. 2025 is the largest year on record at $174,732, 2.4 times the $74,245 reported in 2019. Among psychiatry clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,331 payments — averaging $575.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$182K
- Otsuka America Pharmaceutical, Inc.$115K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$114K
- Alkermes, Inc.$106K
- E.r. Squibb & Sons, L.L.C.$78K
- Axsome Therapeutics, Inc.$59K
- plus $112K from 24 others
Across 877 payments — averaging $8083.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3.8M
- E.r. Squibb & Sons, L.L.C.$3.2M
- Vanda Pharmaceuticals Inc.$64K
- Alkermes, Inc.$2K
- Eli Lilly$1K
What the payments were for
- Consulting fees$80,28210%
- Speaking & faculty fees$628,47982%
- Travel & lodging$28,3234%
- Food & beverage$28,9934%
- Education$4000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 234 | $181,521 |
| Otsuka America Pharmaceutical, Inc. | 190 | $115,184 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 169 | $113,684 |
| Alkermes, Inc. | 139 | $106,026 |
| E.r. Squibb & Sons, L.L.C. | 69 | $78,270 |
| Axsome Therapeutics, Inc. | 62 | $59,449 |
| Vanda Pharmaceuticals Inc. | 93 | $57,302 |
| Teva Pharmaceuticals USA, Inc. | 85 | $30,309 |
| AbbVie(2 entities) | 132 | $20,457 |
| Neuronetics, Inc. | 23 | $1,360 |
| Johnson & Johnson | 37 | $972 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $433 |
| Idorsia Pharmaceuticals US Inc | 7 | $255 |
| Ironshore Pharmaceuticals Inc. | 10 | $203 |
| Lundbeck LLC | 9 | $178 |
| Corium, LLC | 10 | $157 |
| Indivior Inc. | 7 | $141 |
| Tris Pharma Inc | 5 | $136 |
| Supernus Pharmaceuticals, Inc. | 7 | $118 |
| Noven Therapeutics, LLC | 4 | $75 |
| Sun Pharmaceutical Industries Inc. | 2 | $33 |
| Eisai Inc. | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Orexo US, Inc. | 2 | $25 |
| Bausch Health US, LLC | 1 | $24 |
| Braeburn Inc. | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$240,561
- LYBALVI$180,834
- INGREZZA$177,665
- CAPLYTA$110,497
- ABILIFY MAINTENA$84,210
- COBENFY$74,279
- Auvelity$58,224
- Fanapt$55,993
- ARISTADA INITIO$53,608
- ABILIFY ASIMTUFII$42,014
- REXULTI$28,264
- VRAYLAR$18,644
- AUSTEDO$14,915
- UZEDY$11,132
- NEUROSTAR TMS THERAPY$861
- SPRAVATO$227
- QUVIVIQ$113
How this compares
$766,475 in reported general payments places this provider in the 95th percentile of 235 psychiatry providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 63 | $508,996 |
| Invega SustennaPaliperidone Palmitate | 104 | $343,847 |
| AristadaAripiprazole Lauroxil | 89 | $288,459 |
| VraylarCariprazine Hcl | 110 | $157,364 |
| Abilify MaintenaAripiprazole | 42 | $119,262 |
| AustedoDeutetrabenazine | 20 | $117,112 |
| CaplytaLumateperone Tosylate | 55 | $92,507 |
| FanaptIloperidone | 32 | $62,567 |
| AuvelityDextromethorphan Hbr/Bupropion | 43 | $40,110 |
| LybalviOlanzapine/Samidorphan Malate | 24 | $37,434 |
| Risperdal ConstaRisperidone Microspheres | 12 | $31,015 |
| Aripiprazole | 183 | $19,828 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 94 | $16,083 |
| EliquisApixaban | 17 | $10,793 |
| TrintellixVortioxetine Hydrobromide | 22 | $10,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $181,521 | $508,99663 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $972 | $374,862116 claims |
| Alkermes, Inc.Aristada, Lybalvi | $106,026 | $325,893113 claims |
| AbbVieVraylar | $20,457 | $157,364110 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $115,184 | $119,26242 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Loxapine | $30,309 | $119,09869 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $113,684 | $92,50755 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $57,302 | $62,56732 claims |
| Axsome Therapeutics, Inc.Auvelity | $59,449 | $40,11043 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $433 | $16,06235 claims |
| Orexo US, Inc.Zubsolv | $25 | $5,06015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 psychiatry providers in Arkansas.
Other psychiatry in Little Rock
- Tad TillemansLittle Rock$656K
- Paul WylieLittle Rock$54K
- Margaret WeissLittle Rock$29K
- Duong NguyenLittle Rock$14K
- Philip MizellLittle Rock$5K
- Richard FlaniginLittle Rock$5K
- Robert FarrellLittle Rock$4K
- Pawel KuryloLittle Rock$4K
- Gintaras AukstuolisLittle Rock$4K
- Charles LewisLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.